Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
Andrea Casadei-Gardini et al.
LIVER INTERNATIONAL (2021)
DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination
Mengqi Zhu et al.
CELL AND BIOSCIENCE (2021)
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
Wei Cao et al.
CHINESE MEDICAL JOURNAL (2021)
BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
Weiya Cao et al.
BIOMED RESEARCH INTERNATIONAL (2021)
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China
Terry Cheuk-Fung Yip et al.
GASTROENTEROLOGY (2020)
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
John J. Kim et al.
ONCOLOGIST (2020)
Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
Binquan Wu et al.
EXPERT OPINION ON DRUG DELIVERY (2020)
Tumour evolution in hepatocellular carcinoma
Amanda J. Craig et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
p27 as a Transcriptional Regulator: New Roles in Development and Cancer
Seyedeh Fatemeh Razavipour et al.
CANCER RESEARCH (2020)
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
Loraine Kay D. Cabral et al.
CANCERS (2020)
PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma
Yuting Wu et al.
PHARMACOLOGICAL RESEARCH (2020)
CYP2C8 regulated by GAS5/miR-382-3p exerts anti-cancerous properties in liver cancer
Kezhi Li et al.
CANCER BIOLOGY & THERAPY (2020)
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
Weiwei Tang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
Eric Assenat et al.
BRITISH JOURNAL OF CANCER (2019)
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
Lorenza Rimassa et al.
CANCER TREATMENT REVIEWS (2019)
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Fasiha Kanwal et al.
GASTROENTEROLOGY (2019)
Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker
Chuanfei Li et al.
GENE (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Jens Ricke et al.
JOURNAL OF HEPATOLOGY (2019)
Epidemiology and Management of Hepatocellular Carcinoma
Laura Kulik et al.
GASTROENTEROLOGY (2019)
Goals and targets for personalized therapy for HCC
Thomas Couri et al.
HEPATOLOGY INTERNATIONAL (2019)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
Pierce K. H. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Qinlian Jiao et al.
MOLECULAR CANCER (2018)
The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma
Xiangkun Wang et al.
CANCER MEDICINE (2018)
Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries
Hongmei Zeng et al.
LANCET GLOBAL HEALTH (2018)
The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?
Feihu Xie et al.
HEPATOBILIARY SURGERY AND NUTRITION (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma
Xiaojing Ren et al.
BIOMED RESEARCH INTERNATIONAL (2018)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide
Marzia Del Re et al.
CANCER TREATMENT REVIEWS (2017)
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Jordi Bruix et al.
GASTROENTEROLOGY (2016)
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
P-F Zhang et al.
CELL DEATH & DISEASE (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
Janne T. Backman et al.
PHARMACOLOGICAL REVIEWS (2016)
New advances in hepatocellular carcinoma
Sonia Pascua et al.
WORLD JOURNAL OF HEPATOLOGY (2016)
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
Stephen M. Stout et al.
DRUG METABOLISM REVIEWS (2014)
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis
Ruediger Kaspera et al.
PHARMACOGENETICS AND GENOMICS (2010)
Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms
Xin-Sheng Lai et al.
CURRENT DRUG METABOLISM (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
CYP450 pharmacogenetics for personalizing cancer therapy
Ron H.N. van Schaik
DRUG RESISTANCE UPDATES (2008)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacokinetics and pharmacodynamics of rosiglitazone in elation to CYP2C8 genotype
Julia Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Cytochrome P450 pharmacogenetics and cancer
C Rodriguez-Antona et al.
ONCOGENE (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Cytochrome P450 pharmacogenetics and anaesthesia
C Seefelder et al.
PAEDIATRIC ANAESTHESIA (2002)
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
J Liang et al.
NATURE MEDICINE (2002)
Share Paper
